Clinical Trials in New York State

Showing 11161-11180 of 17,167 trials

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

NCT01870037

The primary objective of this study is to evaluate the safety of a single treatment of hMaxi-K compared to placebo (PBS-20% sucrose) administered by direct bladder wall injections. Two dose levels (16000 µg and 24000 µg; 20 or 30 bladder wall injections, respectively) in females with moderate Overactive Bladder/Detrusor overactivity (OAB/DO) of ≥6 months duration will be evaluated. In each dose level, 6 participants will receive hMaxi-K and 3 will receive placebo.

Overactive Bladder

Urovant Sciences GmbH13 participantsStarted Jan 2013

Garden City, New York, United States • New York, New York, United States • Poughkeepsie, New York, United States

COMPLETED67 miles

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

NCT03090464

Type 2 diabetes mellitus is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction. There is evidence that patient support in various forms can have a significant positive impact on adherence to treatment and the meeting of targets in patients with type 2 diabetes mellitus. The purpose of this study is to evaluate if the use of a digital disease management tool (Smart phone- web portal-based tool), in addition to Standard of Care for T2DM, will improve glycemic control. Other variables important in T2DM (such as weight, blood pressure, and lipid levels), will also be evaluated along with patient-reported outcomes, such as satisfaction with treatment and adherence to their antihyperglycemic treatment. Study duration is 6 months

Type 2 Diabetes Mellitus

AstraZeneca328 participantsStarted May 2017

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Peoria, Arizona, United States +43 more locations

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

Find Trials by Condition in New York State

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

The Chimerix CMX001 Registry

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Cardiac Output Measurement by TEE

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

ST266 Versus Standard Care In Treating Partial Thickness Burns

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

A Study for Patients With Acute Leukemia

Fenzian Asthma Multicenter Outcomes Study

BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies